Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE:002020)

SHE:002020 Revenue

Zhejiang Jingxin Pharmaceutical had revenue of 1.06B CNY in the quarter ending June 30, 2026, with 0.35% growth. This brings the company's total for the last twelve months to 4.04B, up 0.37% year-over-year. In the year 2025, Zhejiang Jingxin Pharmaceutical had annual revenue of 4.07B, down -2.14%. That makes Zhejiang Jingxin Pharmaceutical the 10,145th largest company in the world by revenue and 1,646th in China.

• Revenue (ttm): 4.04B
• Revenue Growth: +0.37%
• P/S Ratio: 2.24
• Revenue / Employee: 1.08M
• Employees: 3,732
• Market Cap: 9.10B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Finished drug Business 2.59B 46.8%
• Active Pharmaceutical Ingredient Sales 1.86B 33.6%
• Medical device Business 696.25M 12.6%
• Other Business 392.76M 7.1%

By Geography

Chart

• East China 1.41B 34.6%
• Overseas 856.90M 21.1%
• Central China South China 765.42M 18.8%
• Other Areas 527.75M 13.0%
• North China 509.82M 12.5%

Fiscal year ended Dec 31, 2025 See the full SHE:002020 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.07B	-89.19M	-2.14%
Dec 31, 2024	4.16B	159.72M	3.99%
Dec 31, 2023	4.00B	218.99M	5.79%
Jan 1, 2023	3.78B	313.30M	9.04%
Jan 1, 2022	3.47B	208.47M	6.40%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 27, 2026

Data Sources Report a data error